MedTrace Logo

Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)

NCT02761122 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-07-15

No results posted yet for this study

Summary

Lichen planus is a chronic cutaneous and mucosal disease characterized by the infiltration of cluster of differentiation (CD) CD8 T lymphocytes, localized under the basal membrane and associated with apoptosis of basal keratinocytes, suggesting a reactivity of T lymphocytes toward keratinocyte antigen(s), so far unidentified. In a recent study, the research team at Institut Pasteur has demonstrated in a peculiar clinical form of lichen planus (erosive lichen planus), that the immunogenic target of CD8 T lymphocytes could be the immunodominant peptide of Human Papilloma Virus (HPV) 16.

In line with this recent work which shows for the first time a link between HPV-16 and an autoimmune disease, erosive lichen planus, the aim of te study is to test the hypothesis that HPV could be also involved in the pathogenesis of other clinical forms of lichen, such as non erosive lichen planus or lichen sclerosus.

Conditions

  • Lichen Planus

Interventions

PROCEDURE

Human biological samples

* Blood sample * Skin or mucosal brushing * Skin or mucosal biopsy

Sponsors & Collaborators

  • Société de Dermatologie Française

    collaborator OTHER

  • Institut Pasteur

    lead INDUSTRY

Principal Investigators

  • Marie-Lise Gougeon · Institut Pasteur

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-17
Primary Completion
2018-04-16
Completion
2018-04-16

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02761122 on ClinicalTrials.gov